Why this Dana-Farber collaboration is looking beyond survival in metastatic inflammatory breast cancer
Dana-Farber and Ohio State unite to study how local treatment affects quality of life in metastatic inflammatory breast cancer.
Pharma & Biotech
Pharma & Biotech
Boey can show results in hours and fade in weeks: Why AbbVie is betting shorter can be better
AbbVie wins European approval for Boey, a rapid-onset neurotoxin lasting two to three weeks, opening a new test of aesthetics demand.
Pharma & Biotech
Can a gummy reduce wrinkles in 14 days? What Lemme’s new skin rings actually prove
Lemme launches $30 Ceramosides skin gummy rings for hydration and fine lines, but finished-product evidence will determine long-term credibility.
Pharma & Biotech
Eli Lilly’s psychedelic deal carries a US$3.8bn headline, but the fine print tells the real story
Eli Lilly’s AtaiBeckley deal brings psychedelic medicine into big pharma’s M&A race, but Phase 3 data and rescheduling still decide its value.
Pharma & Biotech
Batlin Recovery Center closes a critical addiction care gap with new 24-hour detox service
Batlin Recovery Center adds ASAM 3.7 medical detox in Missouri, linking 24-hour withdrawal care with residential treatment and recovery services.
Pharma & Biotech
IDEAYA Biosciences expands ESMO 2026 catalyst slate across eye and lung cancer
IDEAYA Biosciences will use ESMO 2026 to expand the clinical case for darovasertib across three uveal melanoma settings and test the durability of IDE849 responses in small-cell lung cancer.
Pharma & Biotech
Why investors just put $315m behind AdvanCell’s prostate cancer alpha therapy
AdvanCell’s US$315 million Series D backs ADVC001 trials and Lead-212 manufacturing, but Phase 2 evidence remains the decisive test.
Pharma & Biotech
PAX Health expands New Jersey medical-legal network with MAKRAF IME acquisition
PAX Health’s acquisition of MAKRAF IME adds a network of psychologists and neuropsychologists spanning 17 New Jersey counties, strengthening the company’s position in behavioral health evaluations, workers’ compensation and medical-legal services.
Pharma & Biotech
South Korea kept Neuronata-R on the market. Now CorestemChemon’s harder test begins
South Korea keeps Neuronata-R available after Phase 3 review, but manufacturing, patient selection and a delayed U.S. filing remain decisive tests ahead.
Pharma & Biotech
Samsung Biologics is buying more than GLP-1 capacity in its CHF 1.46bn PolyPeptide bet
Samsung Biologics’ CHF 1.46 billion PolyPeptide bid adds GLP-1 capacity and six global sites. Read why integration will decide its real long-term payoff.